Thrivent Financial for Lutherans Grows Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Thrivent Financial for Lutherans grew its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 12.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 19,181 shares of the medical instruments supplier’s stock after acquiring an additional 2,190 shares during the period. Thrivent Financial for Lutherans’ holdings in ICU Medical were worth $3,495,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Innealta Capital LLC bought a new position in ICU Medical in the 2nd quarter valued at approximately $32,000. Hexagon Capital Partners LLC raised its stake in shares of ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares in the last quarter. EntryPoint Capital LLC boosted its position in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 0.4 %

NASDAQ:ICUI opened at $167.81 on Tuesday. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of -36.72 and a beta of 0.66. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business has a fifty day moving average price of $175.98 and a 200-day moving average price of $146.15. ICU Medical, Inc. has a one year low of $83.26 and a one year high of $196.26.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,096,771.78. This represents a 10.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. The trade was a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,502 shares of company stock valued at $6,573,496 over the last quarter. 6.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ICUI. KeyCorp upped their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Raymond James increased their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.